LDS/Medical Tests/Biopsy, Breast (Core Needle Biopsy/Fine Needle Aspiration)

Biopsy, Breast (Core Needle Biopsy/Fine Needle Aspiration)

Biopsy of the breast consists of removal of breast tissue for the purpose of pathological examination. It is indicated when a suspicious mass is detected by physical exam (palpable) or when mammography detects suspicious calcifications or areas (non-palpable) in the breast. Depending on the type of lesion and clinical situation, a procedure is selected to provide tissue for pathologic macroscopic and microscopic examination. The amount of tissue removed and the procedure performed varies, and may range from the entire lesion submitted fresh to the laboratory for real-time evaluation (which may include frozen section) as with a lumpectomy, to a small sample removed and submitted in fixative for overnight processing and evaluation, as in needle biopsy.

The purpose of the pathological evaluation is to provide a diagnosis as to benign versus malignant and to provide a description of the characteristics of a malignancy if found, in order to guide subsequent management.

  • As an aid in diagnosing of the breast cancer
  • Diagnosis of other breast related diseases and disorders
  • Pathologic evaluation of the malignancy to establish treatment and disease management
  • Evaluation of the disease and therapy adjustment
  • Prognostic evaluation

Therapeutic decisions are based on the specific pathologic diagnosis. Special stain by IHC of different markers including estrogen and progesterone (ER/PR) as well as other markers such as Her2neu by IHC or FISH are used to aid in diagnosis and treatment.

Normal breast tissue (no pathologic changes)
 

 

Macroscopic examination, microscopic examination of paraffin embedded H&E stained slides, frozen section, microscopic examination of immunohistochemistry stained slides, microscopic and/or computer-aided examination of FISH preparation slides.

Breast tissue biopsy from the affected area, needle aspiration from the affected area. Can be processed and examined as frozen tissue and/or fixed tissue. Collection and handling of each specimen is determined by the procedures requested and indicated at the time of the procedure.

Immmunohistochemistry staining (IHC), Fluorescence in Situ Hybridization (FISH), Gene Expression Profiling by chip array or RT-PCR, Her2/neu by IHC and by FISH, Estrogen and Progesterone hormone receptor assay, Ki-67 proliferation marker assay, DNA ploidy and S-Phase Fraction assay, BRCA 1/2 gene mutation.
Intra-operative Pathologic Macroscopic examination and frozen section generally less than 20 minutes. Microscopic examination and reporting of routinely processed tissue 24 - 48 hours. Prognostic studies (hormone receptors, Her-2 etc) 5 - 7 business days. Predictive studies (gene expression profiling) 14 - 21 business days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Cancer J Sci Am. 1997 Sep-Oct;3(5):273-7. [PMID: 9327150]
  • Arch Pathol Lab Med. 2000; 124(7): 966-78. [PMID: 10888772]
  • Surg Clin North Am. 1996; 76(2): 221-30. [PMID: 8610260]
  • Am J Surg Pathol. 1990 Jun;14(6):578-83. [PMID: 2337206]
  • Powell DE and Stelling CB. The Diagnosis and Detection of Breast Disease, 1st ed. St. Louis, MO: CV Mosby (1994).